Covid-19 roundup: EMA offers early access to Pfizer's pill Paxlovid; Valneva fires back with booster data of its own
The EMA said Thursday that European countries can begin to use Pfizer’s Covid-19 treatment pill Paxlovid, even though it is not yet authorized in the EU.
The pill is indicated to treat adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease.
The early advice is based on clinical trial data from Pfizer showing 1% of patients (6 out of 607) who took Paxlovid within five days of the start of symptoms were hospitalised within 28 days of starting treatment compared with 6.7% of patients (41 out of 612) given placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
